Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

740
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
740
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Hybridoma Technology01:31

Hybridoma Technology

15.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.8K
Cancer Therapies02:49

Cancer Therapies

8.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and Sales.

American journal of hematology·2026
Same author

Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone.

Haematologica·2026
Same author

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

Blood cancer journal·2025
Same author

Human T-Lymphotropic Virus Type 1-Associated Myelopathy With Autoimmune Cholangiopathy: An Unusual Immune Conundrum in a Young Patient.

Case reports in infectious diseases·2025
Same author

The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates.

American journal of hematology·2025
Same author

Cytogenetic abnormalities in polycythemia vera: phenotypic correlates and prognostic relevance in 669 informative cases.

Haematologica·2025
Same journal

Pharmacological approaches for colitis associated colorectal cancer: a survey in preclinical studies.

Cancer treatment and research communications·2026
Same journal

Association of glucagon-like peptide 1 receptor and the aggressiveness of extrahepatic cholangiocarcinoma.

Cancer treatment and research communications·2026
Same journal

The microbiome-epigenome axis: Regulation of host genome function across development and disease.

Cancer treatment and research communications·2026
Same journal

A comparative analysis of cytotoxic effects: Lactobacillus reuteri Extract vs. Newcastle Disease Virus in human colorectal cancer (HT-29 cell line).

Cancer treatment and research communications·2026
Same journal

The influence of CD117, CD133, CD24, CD44, and ALDH expression on progression-free survival in advanced-stage epithelial ovarian cancer patients.

Cancer treatment and research communications·2026
Same journal

Role of microRNA-451a in molecular pathology of cancer.

Cancer treatment and research communications·2026
See all related articles

Related Experiment Video

Updated: Oct 16, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K

Immunotherapy in multiple myeloma.

Yamna Jadoon1, Mustaqeem A Siddiqui2

  • 1Division of Hematology, Mayo Clinic, Rochester MN, United States of America.

Cancer Treatment and Research Communications
|October 15, 2021
PubMed
Summary
This summary is machine-generated.

Multiple Myeloma (MM) is a hematologic malignancy with evolving immunotherapies. This review covers advancements in monoclonal, bispecific, and trispecific antibodies for MM treatment.

Keywords:
Antibody drug conjugatesBispecific antibodiesImmunotherapyMonoclonal antibodiesMultiple myelomaTrispecific antibodies

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Related Experiment Videos

Last Updated: Oct 16, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K

Area of Science:

  • Hematology
  • Immunotherapy
  • Oncology

Background:

  • Multiple Myeloma (MM) is an incurable hematologic malignancy.
  • Significant therapeutic advancements have occurred over the past three decades.
  • Immunotherapy has emerged as a key treatment modality.

Purpose of the Study:

  • To review recent data on novel immunotherapies for Multiple Myeloma.
  • To focus on antibody-based therapies including monoclonal, bispecific, and trispecific antibodies.

Main Methods:

  • Literature review of recently presented and published data.
  • Focus on antibody-based immunotherapies.

Main Results:

  • Daratumumab was the first FDA-approved monoclonal antibody for MM.
  • Elotuzumab and isatuximab are also approved monoclonal antibodies.
  • Numerous clinical trials are investigating newer immunotherapies.

Conclusions:

  • The field of immunotherapy for MM is rapidly expanding.
  • Antibody-based therapies represent a significant area of development for MM treatment.